CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response

Despite their promise, tumor-specific peptide vaccines have limited efficacy. CD27 is a costimulatory molecule expressed on CD4+ and CD8+ T cells that is important in immune activation. Here we determine if a novel CD27 agonist antibody (αhCD27) can enhance the antitumor T cell response and efficacy...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Katherine A. Riccione, Li-Zhen He, Peter E. Fecci, Pamela K. Norberg, Carter M. Suryadevara, Adam Swartz, Patrick Healy, Elizabeth Reap, Tibor Keler, Qi-Jing Li, Kendra L. Congdon, Luis Sanchez-Perez, John H. Sampson
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2018-12-01
coleção:	OncoImmunology
Assuntos:	cd27 tumor immunotherapy peptide vaccine adjuvant monoclonal antibody
Acesso em linha:	http://dx.doi.org/10.1080/2162402X.2018.1502904
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!